Plain-English translation of NCT06601335 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a Phase 3 clinical trial comparing a new combination of two medications called AK112 and AK117 against pembrolizumab (a standard immunotherapy drug) as a first-line treatment for advanced head and neck cancer that has returned or spread. The trial is testing whether this new medication combination is safer and more effective than the current standard approach for people whose tumors have specific markers that make them good candidates for immunotherapy.
Head and neck cancer that has recurred or spread is difficult to treat, and doctors need better options to help patients live longer and with better quality of life. This medication combination represents a new approach to boost the body's immune system against cancer cells, and researchers want to see if it works better than existing treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll be randomly assigned to receive either the new two-drug combination (AK112 and AK117) or pembrolizumab plus a placebo. You'll receive your assigned treatment and have regular clinic visits for check-ups, blood tests, and imaging scans to monitor how well the treatment is working and watch for side effects. The study involves about 510 patients across multiple medical centers and will track your health and treatment response over time.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China